A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia
← catalyst calendarNCT05189639 · readout in 376 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
165estimated
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-05 | actual | When the study began enrolling |
| Primary completion | 2027-08-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-30 | estimated | The whole study's end, after follow-up |
| First posted | 2022-01-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acute Myeloid Leukemia
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)
measured from initiating administration of first dose to the at least 28 calendar days following the last administration of Mylotarg®
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed